| Entry |
|
|---|
| Name |
Cinacalcet hydrochloride (JAN/USAN);
Sensipar (TN);
Mimpara (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C22H22F3N. HCl
|
|---|
| Exact mass |
393.1471
|
|---|
| Mol weight |
393.8729
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
| Product (DG00513): | D03505<JP/US> |
|
|---|
| Efficacy |
Antihypercalcemia, Antihyperparathyroidism, Calcium sensing receptor allosteric modulator |
|---|
| Disease |
Secondary hyperparathyroidism [DS: H01669] Parathyroid carcinoma [DS: H01558] Primary Hyperparathyroidism [DS: H00246] |
|---|
| Comment |
Treatment of hyperparathyroidism and related disorders, such as hypercalcemia (reduction of PTH secretion through modulation of calcium ion receptors on parathyroid cells)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04621 | NOD-like receptor signaling pathway |
| hsa04928 | Parathyroid hormone synthesis, secretion and action |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565]
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H05 CALCIUM HOMEOSTASIS
H05B ANTI-PARATHYROID AGENTS
H05BX Other anti-parathyroid agents
H05BX01 Cinacalcet
D03505 Cinacalcet hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Metabolic Bone Disease Agents
Cinacalcet
D03505 Cinacalcet hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03505 Cinacalcet hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Metabotropic glutamate receptor family
Calcium-sensing
CASR
D03505 Cinacalcet hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03505
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03505
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03505
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03505
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 27
1 C8x C 14.3657 -13.4461
2 C8y C 14.3657 -14.8469
3 C8y C 15.5788 -15.5473
4 C8y C 16.7920 -14.8469
5 C8x C 16.7920 -13.4461
6 C8x C 15.5788 -12.7457
7 C8x C 13.1526 -15.5473
8 C8x C 13.1526 -16.9481
9 C8x C 14.3657 -17.6485
10 C8x C 15.5788 -16.9481
11 C1c C 18.0302 -15.5473
12 N1b N 19.2433 -14.8469
13 C1b C 20.4564 -15.5473
14 C1b C 21.6695 -14.8469
15 C1b C 22.8828 -15.5473
16 C1a C 18.0365 -16.9620
17 C8y C 24.0711 -14.8611
18 C8x C 25.2666 -15.5514
19 C8y C 26.4808 -14.8505
20 C8x C 26.4809 -13.4486
21 C8x C 25.2853 -12.7582
22 C8x C 24.0711 -13.4592
23 C1d C 27.7137 -15.5624
24 X F 28.9108 -16.2538
25 X F 28.4104 -14.3558
26 X F 27.0085 -16.7838
27 X Cl 32.4800 -15.4700
BOND 28
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 2 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 3 10 1
12 4 11 1
13 11 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 11 16 1 #Down
18 15 17 1
19 17 18 2
20 18 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 17 22 1
25 19 23 1
26 23 24 1
27 23 25 1
28 23 26 1
|
|---|
